Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes.
about
Insight to drug delivery aspects for colorectal cancerCAR-modified T-cell therapy for cancer: an updated review.Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in miceChimeric antigen receptors for T cell immunotherapy: current understanding and future directionsTargeted immunotherapy of cancer with CAR T cells: achievements and challenges.The promise and potential pitfalls of chimeric antigen receptors.Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cellsSupernatural T cells: genetic modification of T cells for cancer therapy.Design and development of therapies using chimeric antigen receptor-expressing T cellsChimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.Adoptive transfer of T cells transduced with a chimeric antigen receptor to treat relapsed or refractory acute leukemia: efficacy and feasibility of immunotherapy approaches.A mutant Tat protein provides strong protection from HIV-1 infection in human CD4+ T cells.Inhibition of p38 MAPK activity in B-NHL Raji cells by treatment with engineered CD20-specific T cells.Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model.Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen.Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells.New Approaches in CAR-T Cell Immunotherapy for Breast Cancer.Direct and indirect antitumor effects by human peripheral blood lymphocytes expressing both chimeric immune receptor and interleukin-2 in ovarian cancer xenograft model.
P2860
Q26774682-564A5A45-C814-403D-8F6B-2362E7C3BE2BQ34044213-391B3B4E-0BCA-4170-B86A-F6B9047AFE63Q34244875-730793D6-C270-461E-9185-C4C701F3BB44Q34248531-076F997D-7F70-4E34-BF2D-98B613F832D5Q34270375-B1E45AED-7630-466F-82F9-91900F598A20Q34970378-1BFE8944-6136-4B40-A1D0-A1AF188E5105Q35328354-DE70AE43-1E4B-425C-8847-FD85398FE663Q36328805-A54E74AD-0A5E-4CC3-A008-1B5AD5F76D20Q37418289-4748CD1B-28AC-489A-8862-5EFD9AE527F7Q37861192-2737149F-975F-456F-9D76-7793F9287C6BQ38066860-426BDD58-2924-48BC-ABE0-14708736D11CQ38824622-543FFECD-FCA3-4C8C-BD68-EA31CF939F4CQ39214476-36765FB9-E2FD-41C4-B80D-ADA972118CDBQ39305171-12779EF9-6FC2-4DEB-A2BC-DFEA91DD8FE8Q39641387-B4AB0706-4BB7-4E0C-B0E3-70470C1F4E21Q39903491-4E912E6A-9933-4F42-B5EC-886D9E513D6FQ43143675-93FA2C38-DEDB-4AC7-884F-187CCAC9482FQ43575698-02278138-0650-46D2-9E9F-6BAC2A734BDAQ45862006-AB25A152-7713-4DD8-9EDB-0C353EA5C7DDQ47761448-99A744EC-9E1D-492B-B68B-0DF972849372Q54667188-41E37203-9871-4F48-B2D4-58449BAF58EE
P2860
Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes.
@en
Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes.
@nl
type
label
Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes.
@en
Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes.
@nl
prefLabel
Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes.
@en
Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes.
@nl
P50
P356
P1433
P1476
Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes.
@en
P2093
Maria Moeller
Michele W L Teng
P304
P356
10.1089/1043034041361235
P577
2004-07-01T00:00:00Z